MARKET

ALBO

ALBO

Albireo Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.47
-0.43
-2.16%
After Hours: 20.39 +0.92 +4.73% 17:50 06/24 EDT
OPEN
20.00
PREV CLOSE
19.90
HIGH
20.00
LOW
18.87
VOLUME
325.56K
TURNOVER
0
52 WEEK HIGH
37.86
52 WEEK LOW
17.81
MARKET CAP
381.15M
P/E (TTM)
-11.1270
1D
5D
1M
3M
1Y
5Y
BRIEF-Albireo Presents New BYLVAY (Odevixibat) Data At Annual Espghan Congress
reuters.com · 2d ago
Albireo Presents New Bylvay (odevixibat) Data At Annual ESPGHAN Congress
Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of new data at the annual meeting of the European Society for Paediatric
Benzinga · 2d ago
Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress
Four presentations highlight newest data from landmark Phase 3 PEDFIC 1 and PEDFIC 2 trials, largest studies completed in PFICNew analysis show potential for greater response and higher proportion of pruritus responders with dose escalation and consistent ...
GlobeNewswire · 2d ago
Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases
New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic parametersLong-term data from PEDFIC trials of Bylvay show dramati...
GlobeNewswire · 3d ago
Albireo to Present New Data at the EASL International Liver Congress™ 2022
– Five abstracts accepted, long-term data confirmed durable efficacy with Bylvay™ (odevixibat), with demonstrated improvement in quality of life, growth, and sleep measurements, and hepatic biomarkers in children with all types of PFIC – Two abstracts desc...
GlobeNewswire · 06/08 12:30
Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat) – Three oral presentations discuss long-term safety, tolerability and improved quality of life, hepatic biochemical markers, sleep in children with PFIC – C...
GlobeNewswire · 06/07 12:30
Albireo to Participate at Upcoming Investor Conferences
BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer will be presenting at the following in...
GlobeNewswire · 06/02 20:30
Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022
– Six abstracts presented highlighting data on BylvayTM (odevixibat) and effects on pruritus, serum bile acids, growth and sleep parameters – Pre-clinical study of systemic ASBT/NTCP inhibitors, shows potential of dual-acting ileal/kidney and liver bile ac...
GlobeNewswire · 05/23 12:30
More
No Data
Learn about the latest financial forecast of ALBO. Analyze the recent business situations of Albireo Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALBO stock price target is 70.40 with a high estimate of 80.00 and a low estimate of 66.00.
High80.00
Average70.40
Low66.00
Current 19.47
EPS
Actual
Estimate
-1.030.141.302.46
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 147
Institutional Holdings: 20.08M
% Owned: 102.57%
Shares Outstanding: 19.58M
TypeInstitutionsShares
Increased
29
974.70K
New
22
1.78M
Decreased
39
762.54K
Sold Out
8
899.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Independent Director
David Chiswell
President/Chief Executive Officer/Director
Ronald Cooper
Chief Financial Officer/Treasurer
Simon Harford
Chief Human Resource Officer
Michelle Graham
Chief Scientific Officer
Jan Mattsson
General Counsel/Secretary
Jason Duncan
Other
Martha Carter
Other
Pamela Stephenson
Independent Director
Michael Gutch
Independent Director
Stephanie Okey
Independent Director
Davey Scoon
No Data
No Data
About ALBO
Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.

Webull offers kinds of Albireo Pharma Inc stock information, including NASDAQ:ALBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALBO stock methods without spending real money on the virtual paper trading platform.